Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 16, 2012, reporting events occurring on April 13, 2012. The company is a Delaware corporation headquartered in San Diego, CA.
Key Financial Metrics
The filing details a private placement transaction rather than standard operating financials. Key metrics include:
- Gross Proceeds: $650,000
- Units Sold: 1,300,000 units (each consisting of one share of common stock and one warrant)
- Purchase Price: $0.50 per Unit
- Transaction Costs: $18,000 cash plus 54,000 units issued to a selling agent
- Warrant Terms: Exercisable at $0.50 per share; expire December 31, 2018
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the unregistered sale of equity securities. The company raised $650,000 through the issuance of 1,300,000 units to accredited investors. Additionally, the company entered into a Registration Rights Agreement requiring the filing of a registration statement within 90 days of listing on Nasdaq or NYSE Amex.
Outlook, Risks, and Contingencies
The company relied on the Section 4(2) exemption from registration under the Securities Act of 1933 for this offering. No specific forward-looking guidance, management commentary on future operations, or discussion of risks was included in this specific filing beyond the terms of the warrant and registration rights.
Investor Verification Checklist
- Verify the correct registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the total dilution impact of the 1,300,000 units sold plus the 54,000 units issued to the selling agent.
- Review the attached Form of Warrant (Exhibit 4.1) for specific exercise conditions.
- Monitor the company's listing status on Nasdaq or NYSE Amex to trigger the 90-day registration rights deadline.